Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients
机构：[1]Department 2 of Respiratory Medicine, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing, China,临床科室职能科室呼吸科临床流行病与循证医学中心首都医科大学附属北京儿童医院[2]Key Laboratory of Major Diseases in Children, Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, National Center for Children’s Health, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, Beijing, China,临床科室科研平台职能科室耳鼻咽喉头颈外科临床流行病与循证医学中心儿科研究所首都医科大学附属北京儿童医院[3]Biobank for Clinical Data and Samples in Pediatric, National Center for Children’s Health, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, Beijing, China,科研平台职能科室临床流行病与循证医学中心儿科研究所首都医科大学附属北京儿童医院[4]Department of Laboratory Medicine, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing, China医技科室职能科室检验中心临床流行病与循证医学中心首都医科大学附属北京儿童医院
Background: Childhood refractory mycoplasma pneumoniae (MP) pneumonia (RMPP) is a lung disease with elevated level of C-reactive protein and severe clinical and radiological deterioration. Whether bacterial co-infection contributes to disease of RMPP and whether inclusion of non-anti-MP antibiotics in treatment regimen would benefit RMPP patients remains elusive. Methods: We retrospectively reviewed the medical records of 675 RMPP children. Traditional bacterial culture and next generation sequencing (NGS) were used to detect bacteria in bronchoalveolar lavage fluid in all the 675 patients and 18 patients respectively. Antibiotics used and clinical outcomes were analyzed along with other clinical measurements. Results: Positive bacterial cultures were only found in 18 out of 675 cases (2.67%) and NGS analyses of another 18 cases did not revealed positive bacterial infection, which were consistent with the results of bacterial cultures. Non-anti-MP antibiotics were utilized in 630 cases (93.33%), even last-line antibiotics, such as glycopeptides or carbapenems, were frequently used. Conclusion: Bacterial co-infection in RMPP was rare and non-anti-MP antibiotics didn't show any efficacy for early treatment of RMPP patients, which may provide a rationale for restricting the use of non-anti-MP antibiotics in RMPP patients and preventing antibiotic resistance globally.
基金：
Beijing Municipal and Commission Health and Family Planning [2015-3-076]
第一作者机构：[1]Department 2 of Respiratory Medicine, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing, China,
共同第一作者：
通讯作者：
通讯机构：[1]Department 2 of Respiratory Medicine, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing, China,
推荐引用方式(GB/T 7714)：
Jin-Rong Liu,Jie Lu,Fang Dong,et al.Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients[J].FRONTIERS IN PEDIATRICS.2018,6:-.doi:10.3389/fped.2018.00296.
APA：
Jin-Rong Liu,Jie Lu,Fang Dong,Hui-Min Li,Hui Liu...&Shun-Ying Zhao.(2018).Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients.FRONTIERS IN PEDIATRICS,6,
MLA：
Jin-Rong Liu,et al."Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients".FRONTIERS IN PEDIATRICS 6.(2018):-
